Evidence map›Paper›PMID 41223345›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Amar U Kishan, Luca F Valle, Holly Wilhalme, Carol Felix, Rejah Nabong, Jesus E Juarez-Casillas, Kevin Flores, T Martin Ma, Vinicius Ludwig, Mariko Nakayama and 21 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Dosimetry Analysis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Trial
  2. Review
  3. Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Future of radiotheranostics.BMJ oncology · 2026
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-7437-6591
Luca F ValleDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-5781-4174
Holly WilhalmeDepartment of Medicine Statistical Core, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-8434-6548
Carol FelixDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
Rejah NabongAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Jesus E Juarez-CasillasDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-9604-992X
Kevin FloresDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
T Martin MaDepartment of Radiation Oncology, University of Washington, Seattle, WA.ORCID 0000-0002-0053-7874
Vinicius LudwigAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Mariko NakayamaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Zachary EllsAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-5985-6052
Magnus DahlbomAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Michael LauriaDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-1194-0148
Catherine MeyerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-4542-2608
Minsong CaoDepartment of Radiation Oncology, University of San Francisco, San Francisco, CA.
Joanne B WeidhaasDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-5096-3281
Donatello TelescaDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, CA.
Kristen McGreevyDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-3767-5971
Nicholas G NickolsDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
Danielle KarasikDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
Sophia ParmisanoDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-4054-9546
T Vincent BasehartDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.
Wayne BrisbaneDepartment of Urology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-0470-5262
Leonard MarksDepartment of Urology, University of California, Los Angeles, Los Angeles, CA.
Matthew B RettigGreater Los Angeles VA Medical Center, Los Angeles, CA.
Robert E ReiterDepartment of Urology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-2654-1628
Paul C BoutrosDepartment of Urology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-0553-7520
Martin Allen-AuerbachAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-4292-5824
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-8839-4379

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
Reducing toxicity from prostate cancer radiotherapy through genetics and technologyR37CA292795 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Amar U Kishan · 2024 to 2026
$1.1M
NCI NIH HHS P50 CA211015NCI NIH HHS R37 CA292795NCI NIH HHS T32 CA009213
6 · The paper itself

Abstract

purposeProgression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)-targeting radioligand therapy to SBRT would improve outcomes.

methodsThe LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a

resultsFrom September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and

conclusionCompared with SBRT alone, the addition of

Indexed as

Glutamate Carboxypeptidase IILutetiumNeoplasm Recurrence, LocalProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiosurgeryAgedAged, 80 and overAntigens, SurfaceHumansMaleMiddle AgedNeoadjuvant TherapyPositron Emission Tomography Computed TomographyAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177RadioisotopesRadiopharmaceuticals

Identifiers

PMID41223345
PMCPMC12711279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.